Acarbose might be associated with reduced risk of gastric cancer in patients with diabetes mellitus: A nationwide population‐based cohort study
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5762 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Pili Chih-Min Mao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Acarbose, Stomach Neoplasms. Die Arbeit nennt 72 Literaturangaben. Gefördert von: Kaohsiung Veterans General Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Several epidemiologic studies have revealed a higher risk of cancer in patients with diabetes mellitus (DM) relative to the general population. To investigate whether the use of acarbose was associated with higher/lower risk of new‐onset cancers.
Method
We conducted a retrospective cohort study, using a population‐based National Health Insurance Research Database of Taiwan. Both inpatients and outpatients with newly onset DM diagnosed between 2000 and 2012 were collected. The Adapted Diabetes Complications Severity Index (aDCSI) was used to adjust the severity of DM. The Cox proportional hazards regression model was used to estimate the hazard ratio (HR) of disease.
Results
A total of 22 502 patients with newly diagnosed DM were enrolled. The Cox proportional hazards regression model indicating acarbose was neutral for risk for gastroenterological malignancies, when compared to the acarbose non‐acarbose users group. However, when gastric cancer was focused, acarbose‐user group had significantly lowered HR than non‐acarbose users group ( p = 0.003). After adjusted for age, sex, cancer‐related comorbidity, severity of DM, and co‐administered drugs, the HR of gastric cancer risk was 0.43 (95% CI = 0.25–0.74) for acarbose‐user patients.
Conclusion
This long‐term population‐based study demonstrated that acarbose might be associated with lowered risk of new‐onset gastric cancer in diabetic patients after adjusting the severity of DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
- School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
- Division of Nephrology, Taipei Veterans General Hospital Taitung Branch, Taitung, Taiwan.
- Master Program in Biomedicine, National Taitung University, Taitung, Taiwan.
- College of Health and Nursing, Meiho University, Neipu, Pingtung, Taiwan.
ORCID-Profile: Pili Chih-Min Mao, Mei-Ing Chung, Yao-Min Hung, Hsiu-Min Chen, Chien-Liang Chen
Förderung
- Kaohsiung Veterans General Hospital
Zitieren
APA
Mao, P. C., Chung, M. I., Hung, Y. M., Chen, H. M., & Chen, C. L. (2024). Acarbose might be associated with reduced risk of gastric cancer in patients with diabetes mellitus: A nationwide population‐based cohort study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5762
Vancouver
Mao PC, Chung MI, Hung YM, Chen HM, Chen CL. Acarbose might be associated with reduced risk of gastric cancer in patients with diabetes mellitus: A nationwide population‐based cohort study. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5762
BibTeX
@article{Mao2024,
author = {Mao, Pili Chih-Min and Chung, Mei-Ing and Hung, Yao-Min and Chen, Hsiu-Min and Chen, Chien-Liang},
title = {Acarbose might be associated with reduced risk of gastric cancer in patients with diabetes mellitus: A nationwide population‐based cohort study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5762}
}
EUVIMED